{"data":{"issuanceinfo":{"industrycode":"204005","industry":"醫療保健","ipoprice":{"ceiling":"20.380","floor":"19.380"},"ipodate":{"start":"2018-12-11 00:00:00","end":"2018-12-14 00:00:00"},"minimumcapital":"20585.37","subscribed":"4.79","marketcap":"147.35億","H_marketcap":"30.80億","pe":"--","codesrate":"100.00","link":"https://staticpdf.iqdii.com/stockdata/notice/Prospectus/01877/LTN20181211022_C.pdf","ipopricing":"19.380","resultdate":"2018-12-21 00:00:00","enddate":"2018-12-14 00:00:00","listeddate":"2018-12-24 00:00:00","issuenumber":"15891.00萬","issuenumberhK":"1589.20萬","issuenumberother":"14301.80萬","grayprice":"23.10","sponsors":"中國國際金融香港證券有限公司","raisemoney":"294400.00萬","use":"1、約40%或1177.60百萬港元的所得款項凈額將用于研發及商業化核心產品JS001，為JS001的臨床試驗提供資金；\n2、約16%或471.04百萬港元的所得款項凈額將用于研發其他在研藥品，為臨床試驗提供資金；\n3、約9%或264.96百萬港元的所得款項凈額將用于興建臨港生產基地及吳江生產基地；\n4、約25%或736.00百萬港元的所得款項凈額將用于投資及收購制藥行業的公司，特別是具有與本公司互補的強大研發及/或商業化能力的公司；\n5、約10%或294.40百萬港元的所得款項凈額將用作營運資金及其他一般企業用途。","shares":1000,"leadagent":"中國國際金融香港證券有限公司,花旗環球金融亞洲有限公司,瑞士信貸(香港)有限公司,復星恒利證券有限公司,中信建投(國際)融資有限公司,財通國際證券有限公司","bookrunners":"中國國際金融香港證券有限公司,花旗環球金融亞洲有限公司,瑞士信貸(香港)有限公司,復星恒利證券有限公司,中信建投(國際)融資有限公司,財通國際證券有限公司","coordinator":"中國國際金融香港證券有限公司,花旗環球金融亞洲有限公司,瑞士信貸(香港)有限公司,復星恒利證券有限公司","firstDayOpen":"23.50","IsEiio":0,"Interestdays":7,"PENote":"按經審核的最近年度公司股東應占溢利和發行后總股本計算；發行價未確定時，按招股價中間價計算；發行價確定后，按招股定價計算。","OverAllotment":"有","StabilizingManager":"中國國際金融香港證券有限公司","code":"E01877","name":"君實生物－Ｂ","fullname":"上海君實生物醫藥科技股份有限公司"},"institutioninfo":{"principaloffice":"中國中國(上海)自由貿易試驗區蔡倫路781號602室","registrars":"卓佳證券登記有限公司","registrarstel":"(852)2980 1333","chairman":"熊俊","secretary":"陳英格,黃譯嫻","telephone":"(86021)5079 6193","substantialshareholders":"熊鳳祥(7.70%),熊俊(6.62%),上海檀英(6.68%),蘇州瑞源(5.73%)","principalactivities":"公司是一家創新驅動型生物制藥公司，致力于創新藥物的發現和開發，以及在全球范圍內的臨床研究及商業化。","website":"http://www.junshipharma.com"},"managerinfo":[{"managername":"熊俊","post":"主席、法定代表兼執行董事","rankno":1},{"managername":"李寧","post":"行政總裁、總經理兼執行董事","rankno":2},{"managername":"馮輝","post":"運營總監兼執行董事、","rankno":3}],"investorinfo":[{"institutionname":"Loyal Valley Capital Advantage Fund LP","shareholding":"37,189,000.0","percentage":23.4,"ReleaseDate":"2019-06-24 00:00:00","relatedparty":"林利軍","subsidiary":["Loyal Valley Capital Advantage Fund LP"],"InverstorType":"基金"},{"institutionname":"Highbury Investment Pte Ltd","shareholding":"18,190,000.0","percentage":11.45,"ReleaseDate":"2019-06-24 00:00:00","relatedparty":"GIC Special Investments Private Limited","subsidiary":["Highbury Investment Pte Ltd"],"InverstorType":"公司"},{"institutionname":"王樹君","shareholding":"13,339,000.0","percentage":8.39,"ReleaseDate":"2019-06-24 00:00:00","relatedparty":"深圳德和方中投資有限合伙企業(有限合伙)","subsidiary":["王樹君"],"InverstorType":"個人"},{"institutionname":"俞建午","shareholding":"13,339,000.0","percentage":8.39,"ReleaseDate":"2019-06-24 00:00:00","relatedparty":"宋都基業投資股份有限公司","subsidiary":["俞建午"],"InverstorType":"個人"}],"TotalShareholdingPercentage":61.55},"result":1,"Version":"4.5.190802.46408","ElapsedMilliseconds":10}